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Background: Hepatocyte growth factor (HGF) induced c-Met activation is known as the main stimulus for
hepatocyte proliferation and is essential for liver development and regeneration. Activation of HGF/c-Met signaling
has been correlated with aggressive phenotype and poor prognosis in hepatocellular carcinoma (HCC). MUC1 is a
transmembrane mucin, whose over-expression is reported in most cancers. Many of the oncogenic effects of MUC1
are believed to occur through the interaction of MUC1 with signaling molecules. To clarify the role of MUC1 in
HGF/c-Met signaling, we determined whether MUC1 and c-Met interact cooperatively and what their role(s) is in
hepatocarcinogenesis.
Results: MUC1 and c-Met over-expression levels were determined in highly motile and invasive, mesenchymal-like
HCC cell lines, and in serial sections of cirrhotic and HCC tissues, and these levels were compared to those in
normal liver tissues. Co-expression of both c-Met and MUC1 was found to be associated with the differentiation
status of HCC. We further demonstrated an interaction between c-Met and MUC1 in HCC cells. HGF-induced c-Met
phosphorylation decreased this interaction, and down-regulated MUC1 expression. Inhibition of c-Met activation
restored HGF-mediated MUC1 down-regulation, and decreased the migratory and invasive abilities of HCC cells via
inhibition of β-catenin activation and c-Myc expression. In contrast, siRNA silencing of MUC1 increased HGF-
induced c-Met activation and HGF-induced cell motility and invasion.
Conclusions: These findings indicate that the crosstalk between MUC1 and c-Met in HCC could provide an
advantage for invasion to HCC cells through the β-catenin/c-Myc pathway. Thus, MUC1 and c-Met could serve as
potential therapeutic targets in HCC.
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Hepatocellular carcinoma (HCC) accounts for 85% to
90% of primary liver cancers and is the fifth most com-
mon cancer worldwide [1,2]. More than 250,000 deaths
and 500,000 new cases occur globally each year [1,3].
One of the main reasons for the high mortality rate is
the lack of effective treatments and the development of
resistance to conventional chemotherapy and radiother-
apy [4]. In recent years, improved knowledge of signal-
ing pathways regulating HCC growth and progression* Correspondence: nese.atabey@deu.edu.tr
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reproduction in any medium, provided the orhas led to the identification of several novel molecular
targets. One of the most promising signaling pathways
for molecular therapy of HCC appears to be the Hepato-
cyte Growth Factor (HGF)/c-Met cascade [4-7].
HGF was first characterized as a factor that induces
hepatocyte proliferation and as a motility factor of epi-
thelial cells [8-11]. HGF acts on c-Met, a high affinity
tyrosine kinase receptor, and mediates several cellular
behaviors including cell survival, proliferation, migration
morphogenesis, and angiogenesis [7-21]. Both c-Met and
HGF are overexpressed during liver development and it
is known that the signal elicited through binding of HGF
to c-Met is one of the main stimuli for the G1-S pro-
gression in hepatocytes [13]. In mice, deficiency of either
HGF or c-Met expression causes embryonic lethalityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Bozkaya et al. Molecular Cancer 2012, 11:64 Page 2 of 16
http://www.molecular-cancer.com/content/11/1/64and reduced liver size; whereas, liver-specific deletion of
c-Met induces hepatocyte necrosis and steatosis [14,15].
Furthermore, HGF/c-Met signaling is also essential for
liver regeneration. A severe impairment of liver regener-
ation in the conditional c-Met mutant mice has been
reported [14].
In addition to regulating normal cellular function, c-
Met is implicated in tumorigenesis. Aberrant c-Met
signaling, c-Met mutations, c-Met amplification/overex-
pression, and autonomous growth control through
autocrine signaling loops have been found to be asso-
ciated with carcinogenesis [7-21]. Perturbation of HGF/
c-Met signaling is also involved in aggressive liver
tumors and causes poor prognosis in HCC [15,17]. Re-
cently, You et al. [15] reported that c-Met represents a
potential target of personalized treatment for HCC with
an active HGF/c-Met pathway. While overexpression of
c-Met has been found to be associated with decreased 5-
year survival in patients with HCC [17], deficiency of c-
Met in hepatocytes has been reported to initiate tumori-
genesis in liver [18]. Stoelting et al. [18] published that a
defect in a c-Met-mediated signaling increases
chemically-induced tumor initiation in liver. It also has
been reported that the c-Met regulated gene expression
signature characterizes a subset of HCC with aggressive
phenotypic behavior and poor prognosis [20]. Although
inappropriate HGF/c-Met signaling is involved in all of
these biological processes, in vivo responses are rarely
controlled by one signal; rather, interactions of multiple
signaling pathways are involved. Recent studies have
demonstrated additional roles for the HGF/c-Met signal-
ing cascade in cancer through cross-talk with other sig-
naling cascades, including integrins, class B plexins,
proteoglycan CD44, G-protein coupled receptors, and
many other receptor tyrosine kinases [21]. Many of these
combinatorial signal interactions lead to augmentation
of HGF/c-Met signaling and also contribute to thera-
peutic resistance. Recently, it has been reported that c-
Met interacts with Mucin 1 (MUC1) and catalyzes the
phosphorylation of the MUC1 cytoplasmic C-terminus
in pancreatic cancer cells [22]. MUC1 is the best-
characterized membrane-bound mucin that is expressed
in most epithelial cells and is aberrantly overexpressed
in various cancers, including breast, ovarian, lung, colon,
and pancreatic carcinomas [23,24]. Although MUC1 ex-
pression correlates with high grade, metastasis potential,
and poorer survival rate in breast cancer [25], the studies
about MUC1 expression level in HCC are controversial.
In some studies elevated MUC1 levels have been
reported, while in other reports no differences have been
found [26,27]. It also has been published that the onco-
genic effects of MUC1 are dependent on the cellular
context [28]. Furthermore, it is believed that different
biological responses produced by MUC1 arise due to theparticular repertoire of signaling molecules that interact
with MUC1 [29].
In this study, we hypothesized that the HGF/c-Met
signaling pathway might play diverse roles in hepatocar-
cinogenesis, depending on the MUC1 status of the cells.
To test this hypothesis, we first analyzed MUC1 and c-
Met expression levels in HCC cell lines. In our previous
studies, we characterized the differentiation status of
HCC cell lines as “well-differentiated” and “poorly-differ-
entiated”. Poorly-differentiated, highly motile and inva-
sive HCC cell lines that display a mesenchymal
phenotype were usually deficient in the expression of
hepatocyte lineage markers. However, well-differentiated
cell lines, which have limited motility and invasion abil-
ity and which display an epithelial phenotype, shared
many feature with hepatocytes [30,31]. In this study we
observed that poorly-differentiated HCC cell lines over-
expressed both MUC1 and c-Met, whereas well-
differentiated ones expressed little or no amount of the
MUC1 and c-Met proteins. To support these data we
also analyzed MUC1 and c-Met expression patterns in
primary HCC tissues, as well as in normal and cirrhotic
liver samples. We found that both c-Met and MUC1 ex-
pression were increased during hepatocarcinogenesis
and correlated with the differentiation status of HCC tis-
sues. When we tested the hypothesis that MUC1 might
form a complex with c-Met in the HCC cells, we
observed an interaction between MUC1 and c-Met that
was down-regulated under HGF stimulation. We then
demonstrated that activation and inhibition of HGF/c-
Met signaling and silencing of MUC1 altered the activa-
tion of the c-Met target genes, and cellular motility and
invasion.Results
Both MUC1 and c-Met are overexpressed in poorly-
differentiated HCC cell lines
When we analyzed the expression of MUC1 and c-Met
receptor tyrosine kinase in HCC cell lines (authenticated
by DNA profiling), the cell lines fell into two groups
based on the two expression profiles. Both MUC1 and c-
Met were expressed highly in SNU-475, SNU-449, and
Mahlavu cell lines, which had previously been character-
ized as poorly-differentiated HCC cells. In contrast, both
MUC1 and c-Met were poorly or not expressed in HuH-
7, Hep3B, and Hep G2 cells, which had previously been
defined as well-differentiated HCC cells [30-32]. We
detected two MUC1 bands, one of which represents the
heavily glycosylated mature form (<200 kDa) and the
other represents the poorly glycosylated form
(~170 kDa) of MUC1 [33]. Similar to the MUC1 protein
levels, expression of both the 170-kDa precursor c-Met
and the 145-kDa β subunit of c-Met were higher in
Table 1 Clinicopathological characteristics and MUC1 and
c-met immunostaining of tumors from primary HCC
patients
Parameters n (%)
Gender Male 38 (91)
Female 4 (9)
Tumor Size (cm) ≤3 22 (52)
>3 20 (48)
Nodule number (n) ≤5 37 (88)
>5 5 (12)
Etiology Viral 39 (93)
Alcohol 3 (7)
Tumor Grade Well 7 (17)
Moderate 29 (69)
Poor 6 (14)
Bozkaya et al. Molecular Cancer 2012, 11:64 Page 3 of 16
http://www.molecular-cancer.com/content/11/1/64poorly-differentiated cell lines than in the well-
differentiated cells (Figure 1).
The levels of both MUC1 and c-Met expression are higher
in HCC tissues than in normal and cirrhotic liver samples
MUC1 and c-Met expression profiles were analyzed by
using immunoperoxidase staining. Expression of c-Met
and MUC1 were examined in normal liver (n = 18), cir-
rhotic liver (n = 26), and HCC (n = 42) tissue samples.
The clinicopathological characteristics of HCC patients
are shown in Table 1. In normal liver tissues, both
MUC1 (Figure 2A) and c-Met (Figure 2E) staining were
observed in interlobular bile ducts, but not in normal
hepatocytes. On the other hand, positive staining for
MUC1 (Figure 2B) and c-Met (Figure 2F) were observed
in 27% and 23% of cirrhotic liver tissues sections, re-
spectively. In cirrhotic livers, c-Met was expressed in
proliferating cholangiol and lymphocytes in fibrous septa
as well. MUC1 staining was mainly cytoplasmic in tumor
cells. However, some canalicular staining pattern was
also observed, especially in areas where tumor cells had
formed pseudoglandular structures, which are not read-
ily identified as bile duct differentiation morphologically
on Hematoxylen and Eosin (H&E sections). In HCC tis-
sues, we observed 45% (19/42) positive staining for
MUC1 (Figure 2C) and 64% (27/42) positive staining for
c-Met (Figure 2G). The staining was membranous (4%)
or cytoplasmic (4%) or cytoplasmic and membranous
(92%) in reactive tumor cells for c-Met. In c-Met posi-
tive tumor samples, 11% were scored as one positive,
59% were scored as two positive and 30% were scored as
three positive. Among MUC1 positive HCC patients
32% were scored as one positive, 53% were two positive
and 16% were scored as three positive.
The levels of both MUC1 and c-Met expression were
significantly higher in cirrhotic samples than in normal
tissues (p < 0.05 and p = 0.0025, respectively). The ex-
pression levels of MUC1 and c-Met in HCC were statis-










Figure 1 Expression analysis of MUC1 and c-Met in HCC cell
lines. Total cell lysates were extracted from HCC cell lines to detect
MUC1 and c-Met protein expression by immunoblotting assay. Two
bands were detected for MUC1 due to posttranslational
modification. Precursor protein band (170 kDa) and biologically
active transmembrane β-subunit (140 kDa) of c-Met were detected.
Calnexin was used to verify equal protein loading and transfer.normal (p = 0.0008 and p = 0.0001, respectively) and cir-
rhotic liver tissues (p = 0.005 and p < 0.0001, respectively)
(Figures 2 D-H). There was no correlation between
staining patterns or intensity and none of the clinico-
pathological data (p > 0.05). Since both MUC1 and c-
Met expression levels were correlated with the differen-
tiation status of cell lines, we investigated whether this
profile was observed in patient samples. MUC1-positive
HCC tissues were grouped as follows: 2/7 (29%) well-,
13/29 (45%) moderately-, and 4/6 (67%) poorly-
differentiated (Figures 3A-D). The differences between
the groups were not statistically significant. The levels of
c-Met positive staining were 43% in well-, 69% in
moderately- and 67% in poorly-differentiated HCC tis-
sues. No significant differences were found between the
groups (p > 0.05) (Figures 3E-H).
MUC1 interacts with c-Met in Mahlavu and SNU-449 HCC
cells
To determine whether c-Met interacts with MUC1, we
performed co-immunoprecipitation by using anti-c-Met
antibody in the Mahlavu and SNU-449 cells. As pre-
sented in Figure 1 Mahlavu cells express poorly-
glycosylated form of MUC1 and SNU-449 express
heavily-glycosylated form of MUC1. IP results showed
that c-Met co-precipitates with MUC1 both in Mahlavu
cells (Figures 4 A, B) and SNU-449 cells (Figures 4 C,
D). These results indicated that both heavily and poorly
glycosylated forms of MUC1 can bind the c-Met recep-
tor in the HCC cell lines that we tested. However, we
observed that when compared to Mahlavu cells, a lower
amount of MUC1 is bound to c-Met in SNU-449 cells
which express the heavily glycosylated form of MUC1.
As a control, there was no detectable MUC1 and c-Met
protein in the immunoprecipitates prepared with IgG
alone.




















































Figure 2 Analysis of MUC1 and c-Met expression in normal and cirrhotic liver tissue, and HCC. Negative MUC1 expression in normal
hepatocytes and positive MUC1 expression was localized to bile ducts (×400) (A). Cirrhotic liver tissue showed weak, diffuse cytoplasmic MUC1
staining (×400) (B). HCC displayed intense MUC1 staining (×400) (C). Each column represents histologically classified liver tissues (normal liver,
cirrhotic liver, HCC) with the height representing the ratio of positive staining for MUC1 (D). c-Met expression in normal liver tissue showed very
weak or no immunoreactivity (×400) (E). Cytoplasmic c-Met staining in hepatocytes in the cirrhotic liver tissue (×400) (F). HCC displayed positive
cytoplasmic and strong membranous c-Met staining (×400) (G). Comparison of the ratios of positive staining for c-Met in normal liver, cirrhotic
liver, and HCC tissues (H).





















































MUC1 staining c-Met staining
Figure 3 Immunohistochemical characterization of MUC1 and c-Met expression in HCC tissues relative to tumor differentiation status.
Tissue sections from tumors with well (A, E), moderate (B, F), and poor (C, G) differentiation were assayed for MUC1 (A, B, C) and c-Met (E, F, G)
expression by immunohistochemistry. Each column represents the ratio of positive staining for MUC1 (D) and c-Met (H) in well-, moderate-, and
poorly-differentiated HCC. (E: 200X; A-D, F,G: 400X magnification).
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Figure 4 Identification of MUC1 as an interaction partner for c-Met and effect of HGF on this complex. Endogenous MUC1/c-Met
interaction was carried out in a total cell lysate from Mahlavu cells (A) and SNU-449 (C) using anti-c-Met antibody by IP. The immunoblotting (IB)
with MUC1 showed co-precipitation of endogenous c-Met and MUC1 in unstimulated and HGF stimulated cells. Anti-c-Met antibody was probed
to the membrane as a loading control. There was no detectable c-Met and MUC1 in immunoprecipitates prepared with IgG as an IP-control.
MUC1 signal intensities were measured by scanning the ECL exposed films with a densitometer. The relative MUC1 intensities (mean ± S.E.) for
the different treatments relative to the levels present in the untreated control sample are compared in the bar graphs. Graphs represent data
obtained from Mahlavu cells (B) and SNU-449 cells (D).
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regulated under HGF stimulation
To assess whether activation of c-Met affects its inter-
action with MUC1, Mahlavu and SNU-449 cells were
treated with HGF (40 ng/ml) for 15, 30, and 60 min.
HGF stimulation caused a decrease in the amount of
MUC1 that co-immunoprecipitated with c-Met in a
time-dependent manner both in Mahlavu (Figures 4 A,
B) and SNU-449 cells (Figures 4 C, D). To further assess
the effects of HGF-induced c-Met activation on the
MUC1 expression, we prepared whole cell lysates from
Mahlavu and SNU-449 cells after 15, 30, and 60 min of
HGF treatment. Upon HGF binding, a gradual increase
was observed in the tyrosine phosphorylation of the
catalytic kinase domain at the autophosphorylation site
[pY1234/1235] of c-Met, which reached a plateau at
30 min of HGF stimulation (Figures 5 A, C). Intri-
guingly, synchronous with the c-Met activation, a
marked decrease was observed in MUC1 protein level.
To test the hypothesis that the loss of MUC1 is due to
cleavage of ECD or loss of the protein including the
intracellular domain, we analyzed MUC1 levels in condi-
tioned media and in cytosolic extracts of MUC1 positive
HCC cells in the presence or absence of HGF. While
MUC1 bands were detected in all cell lysates as expected,
we did not observe any MUC1 band in conditioned
media (Additional file 1 Figure S1A). We then used a
second method for quantitative determination of MUC1
antigen in conditioned media. Similarly, no MUC1 wasdetected in the conditioned media from HCC cells by
immunoassay analysis. In addition, we analyzed the
MUC1 protein level in cytosolic extracts in parallel with
total cell extracts. We obtained a similar pattern for
MUC1, which decreased by HGF induction in a time-
dependent manner both in cytosolic (Additional file 1
Figure S1B) and in total cell extracts. If loss of MUC1
was due to cleavage of ECD, then we should have
observed MUC1 bands of lower MW (approximately
30 kDa lower) in cytosolic extracts. As we did not ob-
serve smaller MUC1 bands, we could argue that the loss
of MUC1 is not due to the cleavage of ECD of MUC1 in
HCC cell lines.
HGF treatment increased phosphorylation of c-Met, and
β-catenin and expression of c-Myc
To elucidate the role of MUC1/c-Met interaction and its
down-regulation by HGF, we investigated signaling pro-
teins downstream of both c-Met and MUC1. It is known
that β-catenin interacts with both c-Met and MUC1 [34-
37] and activation of c-Met effects β-catenin expression
and phosphorylation at Ser552 (p-β-catenin-Ser552)
resulting in its nuclear-localization [37,38]. Although
expression of β-catenin was not affected significantly at
the protein level by HGF-stimulation in HCC cells that
we have tested, p-β-catenin levels gradually increased
in response to HGF induction in a time-dependent
fashion. Since phosphorylation at Ser552 plays a role in
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Figure 5 Activation of c-Met signaling pathway by HGF administration induced p42/44-MAPK and β-catenin phosphorylation.
Overnight starved Mahlavu (A, B) and SNU-449 (C, D) cells were stimulated with medium alone and with HGF for 15, 30, and 60 min. Total cell
lysates were then analyzed with Western blotting. Blots were probed with anti-p-Met, anti-c-Met, anti-MUC1, p-p42/44-MAPK, p42/44-MAPK,
anti-p-β-catenin, anti-β-catenin, anti-c-Myc, and anti-calnexin antibodies.
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[34,39]. Expression of c-Myc increased in parallel with
β-catenin phosphorylation under the same conditions
(Figure 5 B, D). We also determined that β -catenin
interacts with MUC1; however, HGF treatment did not
affect their interaction (data not shown).Inhibition of c-Met by SU11274 restores down-regulation
of MUC1 by HGF
We showed above that activation of c-Met led to
decreased MUC1 protein expression in a time-
dependent manner. To further define the influence of c-
Met activation on MUC1 down-regulation, we used
SU11274, a specific inhibitor of c-Met, to block c-Met
activation [40]. HGF induced phosphorylation of c-Met
at the activation loop site phosphoepitope [pY1234/
1235] was reduced by more than half compared to the
HGF stimulated condition by SU11274 (Figure 6A, p-
Met panel). Using SU11274, we restored HGF induced
down-regulation of MUC1 and demonstrated that
MUC1 down-regulation was correlated with c-Met acti-
vation in our experimental system (Figure 6A). More-
over in the presence of HGF, SU11274 also inhibited
HGF-induced β-catenin phosphorylation and c-Mycexpression (Figure 6B). Similar results were observed in
SNU-449 cells (data not shown).
Inhibition of c-met decreases cell motility and invasion
but does not alter proliferation of Mahlavu cells
To further evaluate the role of MUC1 downregulation
by HGF treatment, we determined whether disruption of
this complex affects biological behavior of HCC cells by
performing adhesion, proliferation, migration, and inva-
sion assays. For this aim, we analyzed migration and in-
vasion of cells by using a modified Boyden’s chamber
and matrigel invasion chambers, respectively. We first
showed that HGF alone significantly enhanced the mi-
gratory and invasive capacities of Mahlavu cells (4- and
5-fold, respectively p < 0.0001). When phosphorylation of
c-Met was inhibited by SU11274, there were no signifi-
cant differences in the extent of cell migration and inva-
sion under basal conditions (p > 0.05); however, in the
presence of HGF, the addition of SU11274 caused sharp
decreases in cell motility (p < 0.0001) and invasion
(p < 0.001; Figures 6C, D). Although cellular motility and
invasion were affected profoundly by activation and/or
inhibition of c-Met signaling, adhesion and proliferation
of cells did not changed significantly under similar ex-
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Figure 6 SU11274 selectively inhibited c-Met phosphorylation and downstream signaling. Mahlavu cells were incubated with medium
alone or with SU11274 overnight. Then cells were treated with or without HGF for 60 min. Total protein lysates were analyzed by
immunoblotting. Membranes were blotted with anti-p-Met, anti-c-Met, anti-MUC1 (A), anti-p-β-catenin, anti-β-catenin, anti-c-Myc (B), and anti-
calnexin antibodies. SU11274 pretreated cells and control cells were seeded in the upper chamber of Boyden chambers. No HGF or 40 ng/ml
HGF was added to the lower chamber. Following 24 h incubation, cells that had migrated or invaded onto the lower surface were stained and
counted. Bars represent mean number ± S.E. of migrating (C) or invading (D) cells (* indicates p < 0.05, NS: not significant).
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To determine whether MUC1 down-regulation is re-
sponsible for HGF induced c-Met and β-catenin phos-
phorylation in Mahlavu cells, cells were transfected with
control or MUC1 siRNA oligos. siRNA silencing of
MUC1 caused a significant (p < 0.05) down-regulation of
the MUC1 protein level (Figures 7A, B). Control siRNA
has no effect on MUC1 expression, nor on c-Met and β-
catenin signaling (Figure 7C). Moreover, control siRNA
did not have any effect on cellular motility (p > 0.05)
(Figure 7D), invasion (p > 0.05) (Figure 7E) and prolifera-
tion of Mahlavu cells. In the absence of HGF, siRNA si-
lencing of MUC1 has no effect on c-Met signaling, cell
motility, and invasion of Mahlavu cells (Figures 7C, E).When Mahlavu cells, transfected with MUC1 siRNA for
72 h, were stimulated with HGF for 60 min, significant
increases in the expression and phosphorylation of c-
Met were observed compared to untreated cells
(Figure 8A). Moreover, when MUC1 knockdown cells
are treated with HGF for 60 min, the additive effects of
both HGF induction and MUC1 silencing were seen in
the p-β-catenin levels and its target protein, c-Myc
(Figure 8B).
Silencing of MUC1 increases the cell migration and
invasion capability induced by HGF
MUC1 knockdown cells were significantly more motile
and invasive compared to wild type cells under HGF














































































Figure 7 Inhibition of MUC1 in Mahlavu cells. Inhibition of MUC1 protein expression was demonstrated by siRNA gene silencing targeting of
MUC1 mRNA. Mahlavu cells were transfected with MUC1-specific siRNA and control siRNA and analyzed using immunoblotting with anti-MUC1
antibody (A). Calnexin was blotted as internal loading control. Relative quantification of the MUC1 bands was done using ImageJ. Graph
represents signals obtained from MUC1 bands. Error bars indicate SEM (*indicates p < 0.05, NS: not significant) (B). Total cell lysates from Mahlavu
cells transfected with the control and MUC siRNAs and control siRNA were analyzed by immunoblotting. Membranes were blotted with
anti-p-Met, anti-c-Met, anti-p-β-catenin, anti-β-catenin, anti-c-Myc and anti-calnexin antibodies (C). MUC1 knock-down cells and control cells were
seeded in the upper chamber of Boyden chambers. After 24 h incubation, migrated and invaded cells were counted. Bars represent the
mean ± S.E. of migrating (D) or invading (E) cell number (* indicates p < 0.05).
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http://www.molecular-cancer.com/content/11/1/64treatment (p < 0.001) (Figure 9). However, there were
no statistically significant differences in invasion and
motility for MUC1 siRNA treated cells compared to
the control siRNA treated cells without HGF stimula-
tion (p > 0.05). Moreover, MUC1 silencing did not alter
either the basal or the HGF-induced cell adhesion andHGF : - - +              +






Figure 8 Consequences of MUC1 silencing on downstream signaling
MUC1 for 72 h followed by 60 min HGF stimulation. Controls included no
analyzed by immunoblotting. Membranes were blotted with anti-p-Met, an
anti-calnexin antibodies.proliferation capabilities of Mahlavu cells (data not
shown).
Discussion
The HGF/c-Met pathway is an important regulator of
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molecules. Mahlavu cells were transfected with siRNA targeted to
treatment and MUC1 siRNA-treated cells. Total protein lysates were
































































































































Figure 9 Effect of MUC1 silencing on the cellular motility and invasion. MUC1 and control siRNA treated cells were seeded in the upper
chamber of Boyden chambers. Medium with or without HGF was added to the lower chamber. After 24 h incubation, migrated Mahlavu (A) and
SNU-449 (C) cells and invaded Mahlavu (B) and SNU-449 (D) cells were counted. Bars represent the mean ± S.E. of migrating (A,C) or invading
(B,D) cell number (* indicates p < 0.05).
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of c-Met have been associated with intrahepatic metasta-
sis, vascular invasion, poor prognosis, and drug resist-
ance in HCC [19-21,41]. The role of c-Met in the
phosphorylation of MUC1 in pancreatic cancer progres-
sion has been recently reported [22]. Remarkably, over-
expression of MUC1 in cancer cells correlated with
tumor metastasis, poor prognosis, and resistance to che-
motherapeutic agents [23,42], which suggest that MUC1
and c-Met might work together. However, to our know-
ledge, there is no published study on the role of the po-
tential crosstalk between MUC1 and c-Met in HCC. In
this study, we investigated the possible roles of MUC1
and c-Met in hepatocarcinogenesis and how they inter-
act in this process. We showed that expression patterns
of c-Met and MUC1 correlated with each other and with
the differentiation status of HCC cell lines and tumor
tissues. Moreover, both c-Met and MUC1 expression
levels were significantly higher in HCC tissues than
in cirrhotic and normal liver samples. Furthermore,overexpression of c-Met and MUC1 was observed in
poorly-differentiated and highly motile and invasive
HCC cell lines. Correlated with these findings, we found
MUC1 and c-Met to be expressed at higher levels in
poorly-differentiated primary HCC tissues than in well-
differentiated tumors. The overexpression of the MUC1
and c-Met proteins seen in cirrhotic liver and HCC tis-
sues was not observed in normal liver biopsies. This sug-
gests that the expression of MUC1 and c-Met increases
during transformation of normal liver to HCC. While
this paper was under preparation You et al. [15] demon-
strated that c-Met positive HCC cell lines display a mes-
enchymal phenotype compared to the c-Met negative
cells, which have an epithelial phenotype [15]. The
results of You et al. [15] support our observations that
show poorly-differentiated HCC cells over-express c-
Met, whereas well-differentiated ones do not. Addition-
ally, herein we demonstrate MUC1 over-expression in
the poorly-differentiated mesenchymal-like HCC cells.
Since c-Met is a cell differentiation marker, selective
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cell lines might contribute to the epithelial-mesenchymal
transition during hepatocarcinogenesis.
In addition to their complementary role in HCC devel-
opment and progression, in this study we demonstrate
an association between MUC1 and c-Met in Mahlavu
cells. Singh et al. [22] reported a finding supporting our
observations; namely, they reported that c-Met is an
interaction partner of MUC1 in pancreatic tumor cells.
In addition to the MUC1/c-Met association, we also
showed that HGF stimulation down-regulated the
MUC1/c-Met interaction. When we treated HCC cells
with HGF, we observed a remarkable reduction in
MUC1 levels in a time-dependent manner, while c-Met
expression was unaffected. Additionally, inhibition of c-
Met activation restored MUC1 expression, which clearly
demonstrated that HGF facilitated MUC1 down-regula-
tion. Hence, we argue that in our experimental system
the reduction in the MUC1/c-Met interaction is due to
decreased MUC1 protein levels in response to HGF
inductions. Contrarily, Singh et al. [22] demonstrated
that under HGF stimulation up to 120 min, MUC1 pro-
moted endocytosis and increased turnover of c-Met. To
understand the basis of the differences between HCC
and pancreatic cancer cells we performed a time course
experiment. We did not observe a noticeable down-
regulation of c-Met between MUC1 over-expressing and
MUC1 negative HCC cells during 16 h of HGF induc-
tion (Additional file 2 Figure S2). This is supported by
our IHC analysis which demonstrated that the elevated
levels of both MUC1 and c-Met expression in HCC tis-
sues were correlated positively with each other; namely,
no detectable c-Met down-regulation was observed in
tissues that over-expressed MUC1. Our results also
showed that silencing of MUC1 by siRNA upregulated
HGF-mediated c-Met signaling network. Overall, our
work is distinctive in demonstrating for the first time
the effect of HGF induction both on MUC1/c-Met asso-
ciation and MUC1 protein levels without altering the c-
Met expression pattern. Moreover, in addition to the
modulation of MUC1 by c-Met, we have demonstrated
the regulation of c-Met activity by MUC1.
Singh et al. [22] showed that phosphorylation of the
MUC1 cytoplasmic tail by c-Met activation enhances its
interaction with p53, which leads to a reduction in the
transcription of MMP1 and ultimately decreases inva-
sion when MUC1 is overexpressed. In contrast, we have
shown that MUC1 over-expressing HCC cell lines are
highly motile and invasive. It has been reported that loss
of p53 or the presence of abnormal forms of the p53
protein are common phenotypes in HCC cell lines in-
cluding Mahlavu. Also, mutations of the p53 gene have
been frequently detected in recurrent HCC patients [43-
45]. The differences between the results of Singh et al.[22] and ours might be related to the p53 status of the
HCC cells. To test this hypothesis, we evaluated func-
tional p53 expressions in HCC cell lines examined in
this study, and found no correlation between p53 status
of HCC cells and MUC1 and/or c-Met co-expression or
association (Additional file 3 Table S1). Therefore, the
downstream signaling network of MUC1/c-Met associ-
ation might be independent of p53 in HCC.
Previous studies have indicated that c-Met interacts
with β-catenin at the inner side of the hepatocyte mem-
brane in normal rat liver [34]. After HGF stimulation, c-
Met associated with β-catenin dissociates and translo-
cates to the nucleus [34,35]. Besides being associated
with c-Met, β-catenin also interacts with the cytoplasmic
tail of MUC1 [36]. Putting these findings together, we
questioned whether MUC1 regulates c-Met activity via
β-catenin. Since we did not observe any alteration in the
MUC1/β-catenin interaction depended on HGF stimula-
tion, we therefore examined the effect of HGF induction
on β-catenin expression and phosphorylation. Our stud-
ies demonstrated that the phosphorylation of β-catenin
at Ser-552, which mediates β-catenin migration to the
nucleus [37], was increased by HGF stimulation in a
time-dependent manner. The interaction of c-Met RTK
and β-catenin was reported by Monga SPS et al. in pri-
mary rat hepatocytes and they also identified the domain
in β-catenin which is responsible for this interaction in
rat hepatoma cells [34,46]. Although we demonstrated
β-catenin/MUC1 and MUC1/c-Met interaction in
poorly-differentiated HCC cells, we did not observe
an interaction between β-catenin and c-Met in either
Mahlavu or SNU-449 HCC cell lines in the presence or
absence of HGF. The reason could be the deficiency of
E-cadherin in poorly-differentiated HCC cell lines which
we and others have reported previously [30,31,47]. We
believe that this is an important question that should be
addressed in future investigations.
Nuclear localization of β-catenin is primarily asso-
ciated with the induction of c-Myc expression [34,39].
It has been reported that a rise in the p-β-catenin
level resulted in increased expression of c-Myc, which is
a β-catenin target gene [34,39]. HGF-induced elevation
of p-β-catenin and c-Myc levels observed in our study
implies that β-catenin participates in HGF-mediated c-
Met signaling in HCC cells. When HGF-induced c-Met
activation was blocked by a c-Met specific inhibitor, β-
catenin activation and concurrently c-Myc expression
were suppressed. Interestingly, when MUC1 was
silenced, HGF induced expression and activation of c-
Met increased markedly compared to control cells. In
accordance with c-Met activation, β-catenin activity and
c-Myc expression increased in MUC1-silenced condi-
tions. These results clearly demonstrate that MUC1 is a
potential regulator of HGF/c-Met mediated β-catenin
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activation of β-catenin signaling has been observed
frequently in HCC [30,48,49]; whereas, mutational
activation of β-catenin signaling is found only in about
20-30% of HCCs [49]. Our results suggest that MUC1/
c-Met crosstalk is one of the important regulatory
mechanisms involving aberrant activation of β-catenin
signaling in HCC.
As we reported previously, poorly-differentiated HCC
cells are highly motile and invasive under basal condi-
tions; whereas, well-differentiated cells are not [30]. Since
MUC1 and c-Met are over-expressed and physically
interact in poorly-differentiated HCC cells, we tested the
role of this association on the invasive behavior of these
HCC cells. It has been reported that MUC1 over-
expressing pancreatic tumor cells have higher c-Met sig-
naling activity and a greater tendency to metastasize
when low levels of HGF are present in the tumor micro-
environment [22]. This is supported by the finding that
the invasive ability of pancreatic tumor cells decreased
under HGF stimulation [22]. In this situation, the disrup-
tion of MUC1/c-Met interaction by HGF should decrease
the invasive ability of HCC cells. However, the activation
of HGF/c-Met signaling noticeably increased motility
and invasiveness, despite MUC1 down-regulation of
Mahlavu and SNU449 cells. As expected, the inhibition
of the c-Met signaling network diminished HGF-induced
cell motility and invasion by HCC cells. Interestingly, the
knockdown of MUC1 increases invasion of Mahlavu and
SNU 449 cells in response to HGF stimulation. It seems
that HGF/c-Met mediated MUC-1 down-regulation or
MUC1 silencing increased β-catenin activation and c-
Myc expression, and this might confer a selective advan-
tage for HCC cell invasion. This is supported by a report
showing that elevated c-Myc expression via β-catenin
phosphorylation, in response to HGF stimulation in
colorectal carcinoma cells, is associated with a more
tumorigenic and metastatic phenotype [39]. Since
poorly-differentiated HCC cells are more invasive than
well-differentiated ones, we performed a few experiments
regarding the role of MUC1 and c-Met cooperation on
the differentiation of HCC cells (data not shown). Our
data support that although c-Met and MUC1 co-
expression is very important for cellular differentiation of
HCC cells, presence of HGF in the microenvironment
determines cellular fate. However, due to the limitations
of IHC studies it is difficult to interpret the data in HCC
tissues. Although we used sequential sections from one
paraffin embedded tumor tissue obtained from each pa-
tient for MUC1 and cMet staining, we cannot conclude
that over-expression of MUC1 and c-Met occurs in the
same cells in HCC tissues. In addition as we described
above, HGF levels in the microenvironment affect the be-
havior of MUC1 and c-Met positive cells. Further studiesare needed to clarify the role of MUC1 and c-Met coop-
erativity in HCC cells, including HGF status of the
microenvironment together with c-Met, β-catenin, and
Myc activation status in HCC tissues.
Overall, our data suggests that MUC1 and c-Met are
overexpressed in poorly-differentiated HCC cell lines
and tissues. Under basal conditions, MUC1 and c-Met
interact with each other. The activation of HGF/c-Met
signaling targets MUC1 to reduce its protein level, and
thus prevents the down-regulatory effects of MUC1 on
HGF/c-Met signaling and in turn increases motility and
invasiveness. In support of this model, the inhibition of
HGF-induced c-Met activation restores MUC1 expres-
sion, which results in decreased cellular motility and
invasiveness. Furthermore, the silencing of MUC1
increases HGF induced c-Met activation as well as the
invasion of Mahlavu and 449 cells, showing that MUC1
down-regulation is an important regulator of c-Met acti-
vation in HCC.
Conclusions
In conclusion, the results of this study demonstrate the
modulation of MUC1 by c-Met activation and provide
the first evidence of the regulatory effects of MUC1
on c-Met activity in HCC. We propose that MUC1 and
c-Met have complementary roles during hepatocarcino-
genesis and that their interaction is important for
HGF-induced cellular invasion and metastasis in HCC.
Methods
Cell culture
Human hepatocellular carcinoma cell lines HuH-7,
Hep3B, HepG2, SNU-449, SNU-475, and Mahlavu were
cultured in DMEM supplemented with 10% FBS, 100U/
ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-
glutamine and 1% MEM non-essential amino acids solu-
tion in a humidified 5% CO2 incubator at 37°C. HCC
cell lines were kindly provided by Dr. Mehmet Öztürk
(Bilkent University, Ankara, TR). Authentication of cell
lines was done by DNA profiling at the University of
Colorado Cancer Center (UCCC) DNA Sequencing &
Analysis Shared Resource (CO, USA) using Applied Bio-
system’s Identifiler kit (PN 4322288). Hepatocyte growth
factor/scatter factor (HGF) was from R&D Systems
(MN, USA). HGF (40 ng/ml) was used at specific time
points after overnight starvation in DMEM with 2% FBS.
For the inhibition of c-Met, SU11274 (Calbiochem
448101), was added to the cultures upon start of starva-
tion. DMSO was used as solvent control of SU11274,
which is dissolved in DMSO (Applichem).
Immunoprecipitation
Total cell lysates for immunoprecipitation (IP) and im-
munoblotting (IB) were prepared from HuH-7, Hep3B,
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modified RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM
NaCl, 1 mM EDTA pH 8.0, 1% NP-40, 1x protease in-
hibitor cocktail (Roche, 11836153001) 1 mM NaF, 1 mM
Na3VO4. Protein concentrations of samples were deter-
mined by the BCA assay following the manufacturer’s
instructions (Pierce, IL, USA). 1000 μg of total lysate
was used to analyze the interaction between c-Met and
MUC1 in Mahlavu cells. Samples were incubated with
4 μg anti-MUC1 (sc-7313) or anti-c-Met (c-28) (sc-161)
antibodies for 2 h at 4°C, and then Gamma-Bind Sephar-
ose beads (Amersham 17-0886-01) were added to the
mixture and further incubated overnight at 4°C. IP sam-
ples were then washed three times with IP washing buf-
fer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1 mM EDTA
pH 8.0, 1% NP-40, 0.1x protease inhibitor cocktail
(Roche) 0.1 mM NaF, 0.1 mM Na3VO4). Samples were
re-suspended in 2x loading dye, boiled for 5 min at 95°
C, and bound proteins were analyzed by immunoblot-
ting as described below.
Immunoassays
Total protein and cytosolic extracts were prepared by
using modified RIPA buffer and Fermentas Proteojet
Cytoplasmic and Nuclear Protein Extraction Kit
(K0311), respectively. For immunoblotting equal
volumes of total or cytosolic lysates were loaded onto an
SDS polyacrylamide gel for electrophoretic analysis. The
proteins in the gel were transferred onto PVDF mem-
branes (Pierce), which were first blocked with Tris-
buffered saline with 0.1% Tween-20 (TBST) containing
5% nonfat dry milk for 1 h at room temperature. The
membrane then was blotted with primary antibodies
against phospho-Met (Y-1234/1235) cell signaling 3129,
MUC1 (VU4H5) sc-7313, MUC1 cell signaling 4538,
phospho-p44/42 Erk1/2 (MAPK) (Thr202/Tyr204) cell
signaling 9101, MAPK (ERK1) (C-16) sc-93, β-catenin
(E-5) sc-7963, phospho-β-catenin cell signaling 9566S),
vimentin BD-550513, c-Myc (sc-40) calnexin (sc-11397),
cytokeratin-18 (sc-51582), lamin A/C (sc-7293) in TBST
containing 3% NFDM, and Met (sc-161) in phosphate
buffer saline containing 0.1% Tween-20 and 3% bovine
serum albumin overnight at + 4°C. Proteins were
detected by HRP-conjugated anti-rabbit (Pierce) and
anti-mouse secondary antibodies (Pierce), with
visualization by the ECL detection system (Pierce). The
specific bands were recorded on X-ray film. Equal load-
ing and transfer were confirmed by repeat probing for
calnexin and Coomassie Blue Staining of proteins in
gels. Band intensities were quantified as pixels by using
ImageJ software (NIH). For quantitative determination
of MUC1 antigen in conditioned media the Access Fam-
ily of Immunoassay Systems (MUC1 (CA-15-3), IM2397
Beckman Coulter) was used. The MUC1 epitope(located within the 20-residue tandem repeat domain,
SAPDTRPA) is recognized by B27.29 and DF3 monoclo-
nal antibodies in this system.
siRNA mediated knock down of MUC1
To silence MUC1, Mahlavu cells were transfected with
500nM siRNA (ON-TARGETplus SMARTpool siRNA
L-004019-01-0020 Dharmacon) for 72 h using Fugene
HD Transfection Reagent (Ref 04 709 705 001). Non-
targeting siRNA (control siRNA-A: sc-37007) was used
as scramble control. After 72 h incubation, cells were
harvested or replated for subsequent experiments.
Motility and invasion assay
In-vitro motility and invasion assays were performed as
described [28]. The migration of Mahlavu cells was mea-
sured by Biocoat Cell Environment control inserts (8-
μm pore size; BD Biosciences). Invasion assays with the
same cell line were carried out using Matrigel Invasion
Chambers (BD Bioscience). Briefly, cells transiently
transfected with 500 nM MUC1 siRNA (as described
above) or cells pretreated overnight with 1.5 μM
SU11274 in DMEM with 5% FBS were placed in upper
chambers. Untreated and control siRNA treated cells
were used as controls. 5,000 cells were inoculated into
each chamber. After 24 h incubation at 37oC, the
medium was removed and cells were fixed and stained
with Diff Quick (Siemens Healthcare Diagnostics). Cells
on the upper portion of the membrane were wiped off
with a cotton-tipped swab and cells that had traversed
through the membrane were counted using a bright-
field inverted microscope. Total cell numbers were
counted for each chamber. Experiments were performed
in at least triplicates. Bars represent fold differences in
mean migrating or invading cell numbers. Fold differ-
ences were calculated by dividing the experimental
results by the control results.
Cell adhesion and proliferation assay
SiRNA or SU11274 pretreated and untreated and/or
HGF stimulated Mahlavu cells were plated on the 96 E-
Plate (Roche). Adhesion and proliferation were moni-
tored in a real-time cell electronic sensing RT-CES sys-
tem (xCeLLigence-Roche Applied Science) for 96 h.
These experiments were performed in at least triplicate.
Histopathology
Tissue samples were obtained from 42 patients with
HCC and a cirrhotic history and 26 patients with only
cirrhosis. They all had received transplants in Dokuz
Eylul University, Izmir, Turkey. Normal donor liver biop-
sies were used as controls. The study was approved by
the Ethics Committee of Dokuz Eylul University Medical
School. Written informed consents were obtained from
Bozkaya et al. Molecular Cancer 2012, 11:64 Page 14 of 16
http://www.molecular-cancer.com/content/11/1/64patients before liver transplantation or liver biopsy sam-
pling. All tissue samples were fixed in formalin and em-
bedded in paraffin. Archival materials of the patients
were reevaluated by a certified pathologist (ÖS) for the
confirmation of the diagnosis and to choose the most
appropriate tissue block for immunohistochemistry. The
histopathological analyzes of all patients were carried
out by the WHO histopathological classification of liver
and intrahepatic bile ducts [29]. Standard 5 μm tissue
sections were taken on lysine-coated slides.
Immunohistochemical procedure
Sections were deparaffinized in xylene and then rehy-
drated. Immunostaining was performed using an auto-
mated immunohistochemical stainer according to the
manufacturer’s guidelines (Biogen, Lab vision autostainer
360). The antigen retrieval was performed by treatment
of proteinase K for 20 min at 37oC. Endogenous perox-
idase activity was blocked by incubation with 3% H2O2
for 15 min at room temperature. Tissues were incubated
for 9 min with avidin-biotin blocking solution (SkyTek
Lab.), and then primary antibodies anti-MUC1 (sc-7313)
or anti-c-Met (sc-161) were applied at 1:100 dilutions
and incubated for 35 min. The sections were stained
with 3, 3-diaminobenzidine tetrahydrocloride (DAB), a
chromogen stain (brown in color), and counterstained
with hematoxylin.
Evaluation of staining
All staining was semi-quantitatively evaluated by a certi-
fied pathologist (ÖS). Expression of c-Met was defined
as membranous and/or cytoplasmic when more than
10% of the hepatocytes stained positive for c-Met. The
extent of staining was scored as one positive (10% to
25% of cells were positively stained), two positive (25%-
50% of cells were positively stained) and three positive
(more than 50% of the cells were positively stained).
Staining with MUC1 antibody was defined as cytoplas-
mic and canalicular staining in hepatocytes and the ex-
tent of staining was again scored semi-quantitatively. If
less than 10% of hepatocytes expressed MUC1 antibody
this staining was scored as one positive staining between
10% and 30% of cells, and staining in more than 30% of
cells were regarded as two and three positive, respect-
ively. The intensity of MUC1 and c-Met immunostaining
was semiquantitatively graded as follows: none (0), weak
(+1), moderate (+2), and intense (+3).
Statistical analysis
All data for motility and invasion assays were expressed
as mean ± S.E. Statistical analysis was performed using
the GraphPad Prism and Statistical Package for Social
Sciences 15.0 (SPSS Inc., Chicago, IL, USA). Statistical
methods included Analysis of variance (ANOVA),Mann–Whitney U test, and ×2-test. ANOVA was used
in the case of comparison of multiple groups. Mann–
Whitney U test and ×2-test were used for the evaluation
between two points as appropriate. Overall survivals of
cells were computed using the Kaplan-Meier method
and comparison between groups were analyzed using
the log-rank test. Correlation between two groups was
assessed by Pearson’s correlation analysis. p < 0.05 was
considered statistically significant.Additional files
Additional file 1: Figure S1. Effect of HGF stimulation on c-Met
expression in MUC1 negative and, MUC1 over-expressed HCC cells. MUC1
negative well-differentiated HuH-7 cells (A) and MUC1 over-expressing
poorly-differentiated cells SNU-449 (B) and Mahlavu (C) were treated with
HGF at the indicated times. After treatment, cells were lysed and
subjected to immunoblotting using anti-c-Met and anti-calnexin
antibodies. Calnexin was used as a loading control.
Additional file 2: Figure S2. Investigation of MUC1 in total and
cytosolic cell extracts and conditioned media. Overnight starved Mahlavu
cells were treated with medium alone and with HGF for 15, 30, 60 min.
Conditioned media were collected and total protein extracts obtained at
the indicated time points after HGF administration. Then total protein
extracts and conditioned media analyzed by Western Blotting for MUC1
expression (A). Simultaneously cytosolic cell extract were prepared and
analyzed for MUC1 expression. Cytokeratin-18 used for equal loading and
transfer control for cytosolic extracts. Lamin A/C used for verifying that
nuclear protein did not leak into the cytosolic cell fraction during cell
fractionation (B).
Additional file 3: Table S1. P53 status and the expression levels of
MUC1 and c-Met in HCC cell lines. (NF: non-functional, F: functional, ND:
not determined, high: high level protein expression, low: low level
protein expression).
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